A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nsclc Patients With Egfr Or Human Epidermal Growth Factor Receptor 2 (her2) Mutations.
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytologically confirmed diagnosis of non-squamous NSCLC, locally advanced or metastatic
    2. Have written documentation of EGFR Exon20ins mutation in tumor tissue
    3. Participants should be newly diagnosed o

You may not be eligible for this study if the following are true:

    1. Prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic NSCLC
    2. Prior treatment with any EGFR Exon20ins inhibitors, including poziotinib, mobocertinib, CLN-081, furmonertinib, etc. or prior treatmen

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.